Vulva ve Vajen Kanseri
Özet
Vulva ve vajina kanserleri, kadın üreme sistemini etkileyen nadir kanser türleridir. Vulva kanseri dış genital bölgeden, vajina kanseri ise vajinadan gelişir. İleri yaş kadınlarda daha sık görülür ve HPV enfeksiyonu gibi faktörler riski artırabilir. Tedavi genellikle cerrahi, radyoterapi, kemoterapi ve/veya immünoterapiyi içerir. Tedavi sonrası düzenli takip, nüksün erken teşhisi, tedavi yan etkilerinin yönetimi ve hastaların yaşam kalitesinin artırılması için kritik öneme sahiptir. Takipte; fizik muayene, gerekirse görüntüleme ve laboratuvar testleri, ürogenital ve psikososyal değerlendirme yapılır. Ayrıca, hastalara tedavi ve takip protokolleri hakkında detaylı bilgi verilir ve gerekirse uzmanlara yönlendirilir.
Takibin temel amacı, genel sağlık durumunun iyileştirilmesi, kronik hastalıkların kontrolü, kardiyovasküler risklerin takibi, sağlıklı yaşam alışkanlıklarının benimsenmesi ve tedavinin uzun dönemli etkilerinin değerlendirilmesidir. Vulva kanseri takibinde vulva ve inguinal lenf nodlarının muayenesi, HPV testi/sitoloji ve gerekirse görüntüleme yapılır. Vajina kanseri takibinde ise fizik muayene, gerekirse görüntüleme ve sitoloji testleri uygulanır. Her iki kanser türünde de nüks riski zamanla azalmakla birlikte devam ettiği için uzun süreli takip önemlidir. Takip protokolleri, hastanın bireysel risk faktörlerine göre kişiselleştirilmelidir.
Vulvar and vaginal carcinomas represent uncommon gynecological malignancies impacting the female reproductive tract. Vulvar carcinoma arises from the external female genitalia, whereas vaginal carcinoma originates within the vaginal canal. These malignancies are more frequently observed in elderly women, with factors like human papillomavirus (HPV) infection contributing to increased risk. Therapeutic interventions commonly encompass surgical excision, radiation therapy (RT), chemotherapy, and/or immunotherapy. Post-treatment surveillance is paramount for early detection of disease recurrence, management of treatment-related adverse events, and optimization of patient quality of life. Surveillance protocols incorporate physical examination, imaging modalities and laboratory investigations as clinically indicated, alongside urogenital and psychosocial evaluation. Furthermore, patients receive comprehensive information regarding treatment strategies and follow-up schedules, with referral to appropriate specialists as deemed necessary.
The overarching objective of surveillance is to achieve optimal general health status, manage pre-existing chronic conditions, monitor cardiovascular risk factors, promote the adoption of healthy lifestyle practices, and assess the long-term sequelae of treatment. Surveillance for vulvar carcinoma includes assessment of the vulva and inguinal lymph nodes, HPV testing/cytological examination, and diagnostic imaging when indicated. In the context of vaginal carcinoma surveillance, physical examination, imaging studies, and cytological analysis are performed as clinically warranted. Given the persistent, albeit diminishing, risk of recurrence in both cancer types, long-term follow-up is essential. Surveillance protocols should be tailored to each patient's unique risk profile.
Referanslar
Lin KY, Frawley HC, Denehy L, et al. Exercise interventions for patients with gynaecological cancer: a systematic review and metaanalysis. Physiotherapy 2016;102:309-319.
Nekhlyudov L, Mollica MA, Jacobsen PB, et al. Developing a Quality of Cancer Survivorship Care Framework: Implications for Clinical Care, Research, and Policy. J Natl Cancer Inst 2019;111:1120-1130.
Bober SL, Reese JB, Barbera L, et al. How to ask and what to do: a guide for clinical inquiry and intervention regarding female sexual health after cancer. Current Opinion in Supportive and Palliative Care 2016;10.
Campbell G, Thomas TH, Hand L, et al. Caring for Survivors of Gynecologic Cancer: Assessment and Management of Long-term and Late Effects. Semin Oncol Nurs 2019;35:192-201.
SGO/FWC Survivorship Toolkit. Available at: https://www.sgo.org/resources/survivorship-toolkit/.
W.J. Koh, B.E. Greer, Vulvar cancer, version 1.2017, NCCN clinical practice guidelines in oncology, J. Natl. Compr. Cancer Netw. 15 (1) (2017) 92–120.
N.C. Te Grootenhuis, A.G.J. van der Zee, H.C. van Doorn, et al., Sentinel nodes in vulvar cancer: long-term follow-up of the GROningen International Study on Sentinel nodes in Vulvar cancer (GROINSS-V) I, Gynecol. Oncol. 140 (2016) 8–14.
Maggino T, Landoni F, Sartori E, et al. Patterns of recurrence in patients with squamous cell carcinoma of the vulva. A multicenter CTF study. Cancer 2000;89:116–22.
Buchanan TR, Zamorano AS, Massad LS, et al. Risk of cervical and vaginal dysplasia after surgery for vulvar intraepithelial neoplasia or cancer: a 6 year follow-up study. Gynecol Oncol 2019;155:88–92.
Kuroki LM, Frolova AI, Wu N, et al. Yield of cytology surveillance after high-grade vulvar intraepithelial neoplasia or cancer. J Low Genit Tract Dis 2017;21:193–7.
Oonk MHM, de Hullu JA, Hollema H, et al. The value of routine follow-up in patients treated for carcinoma of the vulva. Cancer 2003;98:2624–9.
Te Grootenhuis NC, van der Zee AGJ, van Doorn HC, et al. Sentinel nodes in vulvar cancer: long-term follow-up of the Groningen International Study on Sentinel Nodes in Vulvar Cancer (GROINSS-V) I. Gynecol Oncol 2016;140:8–14.
Pouwer AW, Mus R, IntHout J, et al. The efficacy of ultrasound in the follow up after a negative sentinel lymph node in women with vulvar cancer: a prospective single-centre study. BJOG 2018;125:1461–8.
Gonzalez Bosquet J, Magrina JF, Gaffey TA, et al. Long-term survival and disease recurrence in patients with primary squamous cell carcinoma of the vulva. Gynecol Oncol 2005;97:828–33.
Röhrmoser K, Ignatov A, Gerken M, et al. Risk factors and temporal patterns of recurrences in patients with vulvar cancer: implications for follow-up intervals and duration. J Cancer Res Clin Oncol 2023;149:803–10.
Zapardiel I, Iacoponi S, Coronado PJ, et al. Prognostic factors in patients with vulvar cancer: the VULCAN study. Int J Gynecol Cancer 2020;30:1285–91
te Grootenhuis NC, Pouwer AW, de Bock GH, et al. Margin status revisited in vulvar squamous cell carcinoma. Gynecol Oncol 2019;154:266–75
Kilcoyne A, Gottumukkala RV, Kang SK, et al. ACR Appropriateness Criteria® Staging and Follow-up of Primary Vaginal Cancer. J Am Coll Radiol 2021;18:S442-s455.
Salani R, Khanna N, Frimer M, et al. An update on post-treatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncology (SGO) recommendations. Gynecol Oncol 2017;146:3-10.
Bodurka-Bevers D, Morris M, Eifel PJ, et al. Posttherapy surveillance of women with cervical cancer: an outcomes analysis. Gynecol Oncol 2000;78:187-193.
Morice P, Deyrolle C, Rey A, et al. Value of routine follow-up procedures for patients with stage I/II cervical cancer treated with combined surgery-radiation therapy. Ann Oncol 2004;15:218-223.
Elit L, Fyles AW, Devries MC, et al. Follow-up for women after treatment for cervical cancer: a systematic review. Gynecol Oncol 2009;114:528-535.
Chung HH, Jo H, Kang WJ, et al. Clinical impact of integrated PET/CT on the management of suspected cervical cancer recurrence. Gynecol Oncol 2007;104:529-534.
Dessources K, Aviki E, Leitao MM, Jr. Lower extremity lymphedema in patients with gynecologic malignancies. Int J Gynecol Cancer 2020;30:252-260.
Bona AF, Ferreira KR, Carvalho RBM, et al. Incidence, prevalence, and factors associated with lymphedema after treatment for cervical cancer: a systematic review. Int J Gynecol Cancer 2020;30:1697-1704.
Loprinzi CL, Lacchetti C, Bleeker J, et al. Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline Update. J Clin Oncol 2020;38:3325-3348.
Stahl JM, Qian JM, Tien CJ, et al. Extended duration of dilator use beyond 1 year may reduce vaginal stenosis after intravaginal high-doserate brachytherapy. Support Care Cancer 2019;27:1425-1433.
Park HS, Ratner ES, Lucarelli L, et al. Predictors of vaginal stenosis after intravaginal high-dose-rate brachytherapy for endometrial carcinoma. Brachytherapy 2015;14:464-470.
Dracham CB, Shankar A, Madan R. Radiation induced secondary malignancies: a review article. Radiat Oncol J 2018;36:85-94.
Borella F, Preti M, Bertero L, et al. Is There a Place for Immune Checkpoint Inhibitors in Vulvar Neoplasms? A State of the Art Review. Int J Mol Sci 2020;22.
Schepisi G, Casadei C, Toma I, et al. Immunotherapy and Its Development for Gynecological (Ovarian, Endometrial and Cervical) Tumors: From Immune Checkpoint Inhibitors to Chimeric Antigen Receptor (CAR)-T Cell Therapy. Cancers (Basel) 2021;13.
Hefler L, Obermair A, Tempfer C, et al. Serum concentrations of squamous cell carcinoma antigen in patients with vulvar intraepithelial neoplasia and vulvar cancer. Int J Cancer. 1999;84:299-303
